# Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

> **NCT03447678** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 65 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03447678
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-23
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447678, "Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03447678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*